Because the mechanism of action of SGLT2 inhibitors is independent of insulin secretion or action, this class is considered to be complementary to existing drugs for the treatment of diabetes, effective in all stages of the disease, used alone or in combination with metformin, sulphonylureas, thiazolidinediones or insulin in patients with an acceptable renal function [28,29,30]. The gene discussed is INS; the disease is diabetes mellitus.